Table 1

Patient data

Patient no.SexAge (yr)Tumor stagingaLocation of primary tumorVmb (cm3)Classification of responsec
6 wk3 mo
1F76T3N2cM0Oropharynx13.5PRPR
2M57T4N2bM0Oropharynx, tongue base20.0PRCR
3M41T4N2cM0Oro-/Hypopharynx5.0CRCR
4M56T4N1M0Hypopharynx4.2PRPR
5F62T3N2bM0Oropharynx1.2PRCR
6M41T4N2cM0Hypopharynx7.0SDPR
7M55T4N2cM0Oropharynx41.0SDSD
8M54T4N2cM0Oro-/Hypopharynx6.0SDPD
9M68T2N3M0Oropharynx450dCRCR
10M47T4N3M0Hypopharynx, larynx500dPR e
11M50T3N1M0Tongue1.8 f CR
12M39T4N2cM0Oro-/Hypopharynx100dPRPR
13M49T4N2cM0Oropharynx5.0SD g
14M59T4N3M0Mouth floor, oropharynx125d f f
15F42T4N2cM0Oropharynx11.5PRPR
16M58T4N2cM0Larynx/Hypopharynx17.0PR f
17M54T4N2cN0Oropharynx5.3PR f
  • a Classification according to TNM (tumor, node, metastasis) system (16) .

  • b Vm, volume of neck metastasis.

  • c Volume changes of examined lymph node metastases classified according to WHO criteria; PR, partial remission (reduction of tumor size by 50% or more); CR, partial remission (complete disappearance of the tumor); SD, stable disease (reduction of tumor size by less than 50% or increase of tumor size by less than 25%); PD, progressive disease (increase of tumor size by more than 25%).

  • d Rough estimate in the case of large lymph node conglomerates.

  • e Not evaluated after 3 months; the patient developed cutaneous filiae 2 months after treatment.

  • f Not evaluated.

  • g The patient died from tumor bleeding.